Navigation Links
Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
Date:9/13/2007

"expect," "estimate," "intend," "should," "would," "could," "will," "may" or other similar expressions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: the results of clinical trials with respect to Sucampo Pharmaceuticals' products under development; the timing and success of submission, acceptance and approval of regulatory filings; Sucampo Pharmaceuticals' dependence on the commercial success of AMITIZA; Sucampo Pharmaceuticals' ability to obtain additional funding required to conduct its discovery, development and commercialization programs; Sucampo Pharmaceuticals' dependence on its co- marketing alliance with Takeda Pharmaceutical Company Limited; and Sucampo Pharmaceuticals' ability to obtain, maintain and enforce patent and other intellectual property protection for its discoveries. These and other risks are described in greater detail in the "Risk Factors" section of Sucampo Pharmaceuticals' quarterly report on Form 10-Q filed with the Securities and Exchange Commission on August 22, 2007. Any forward-looking statements in this press release represent Sucampo Pharmaceuticals' views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Sucampo Pharmaceuticals anticipates that subsequent events and developments will cause its views to change. However, while Sucampo Pharmaceuticals may elect to update these forward-looking statements publicly at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise.

Contact:

Scott Solomon

Vice President

Sharon Merrill Associates, Inc.

617-542-5300

David Buckalew

Takeda Pharmaceuticals North America, Inc.

224-554-5486


'/>"/>
SOURCE Sucampo Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
4. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
5. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
6. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
7. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
8. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
9. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
10. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
11. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/hcb7bz/pharmaceutical ) has announced ... UK - November 16-18, 2015)" conference to their offering. ... including Columbia, Peru , Brazil ... Uruguay , Paraguay , Venezuela ... , Chile This seminar can be ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cnq7tc/medical_device ) has ... Studies: Clinical Evidence (London, UK - November 10-11, ... This course has been designed specifically for ... required for medical devices and in-vitro diagnostic products. ... and the emphasis on high quality, appropriate clinical ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/r6wspz/drug_delivery_in ) ... report "Drug Delivery in Central Nervous System ... their offering. Advances in understanding ... opened new avenues and possibilities for improved drug ... systems, enzymes, and receptors that control the penetration ...
Breaking Medicine Technology:Pharmaceutical Regulatory Affairs in Latin America Seminar - London, UK - November 16-18, 2015 2Medical Device Studies: Clinical Evidence Course - London, UK - November 10-11, 2015 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 3
... Broadspire, a Crawford Company (NYSE: CRDA ; CRDB) ... provider, is proud to announce that Gary Anderberg, Ph.D., practice ... of Risk & Insurance magazine,s 2010 Risk Innovator ... a leader with Broadspire,s e-Triage system, which helps analyze claims ...
... Pa., Sept. 15 The GBS /CIDP ... symposium on Guillain-Barre Syndrome (GBS) and Chronic Inflammatory ... 5-7, 2010.  Over 400 medical professionals, current and former ... expected to attend the three-day event at the Dolce ...
Cached Medicine Technology:Broadspire’s Gary Anderberg Named a 2010 Risk Innovator 2Broadspire’s Gary Anderberg Named a 2010 Risk Innovator 3GBS/CIDP Foundation to Hold 11th International Symposium 2
(Date:9/3/2015)... ... September 03, 2015 , ... ... triggering cost increases for fully insured employer-sponsored health insurance plans, more employers are ... employees), according to data released from the 2014 United Benefit Advisors (UBA) Health ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... endpoint data collection, cloud analytics and workflow solutions today announced the complete ... Portugal, September 22-24, 2015. The esteemed faculty of worldwide pharmaceutical and industry ...
(Date:9/3/2015)... ... , ... AvePoint, the established leader in enabling enterprise collaboration across ... – AvePoint’s solution for facilitating two-way collaboration and external sharing without ever having to ... is the fifth consecutive year an AvePoint product has made the list. , The ...
(Date:9/3/2015)... ... September 03, 2015 , ... The new In-Office ... of Provo, Utah. The Clinicians Report is a leading information source to the ... throughout the U.S. Whiter Image's In-Office whitening kits were favorably validated for use ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... Local filmmakers ... April Hannah & Michael Habernig from Path 11 Productions have had great success in ... age podcast has featured Hay House authors, Teal Swan who is the well known ...
Breaking Medicine News(10 mins):Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 2Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 4Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 2Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 3Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 2Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 3Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 4Health News:Whiter Image Products Get Positive Rating From The Clinicians Report 2Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 2Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 3
... may be able to help people// suffering from fibromyalgia. ... of Florida the cough medicine seemed to bring relief ... from fibromyalgia. ,Fibromyalgia syndrome occurs with extensive musculo-skeletal ... this diseases. More women than men report to be ...
... that asthmatic women have tendency of// irregular menstruation. ... severe stress, serious disease, anorexia nervosa, and drug addiction. ... women for 8 years to understand the possible link ... the research said that younger women with asthma and ...
... Scientists said that the problem of inability to read ... in visual processes as was thought in recent years. ... of perception than anything else. ,Dyslexia is one ... children, who have difficulty in verbal skills, abstract reasoning, ...
... researchers have established the association between adult urinary incontinence ... than 1000 Turkish women, the research says that the ... same for exhibiting lack of control in controlling urine ... may suffer from some faulty neural pathway that connects ...
... apnea syndrome affects a lot of people who are ... of having a difficult night, these people may have ... ,Obstructive sleep apnea syndrome (OSAS), also known as the ... problems, stroke, obesity, breathing problems, sexual dysfunction and clinical ...
... Women who had been diagnosed with breast cancer need to ... with lowering of levels of ovarian hormones and this could ... cancer patients who regularly exercised for about an hour daily. ... Health Study who were diagnosed with breast cancer of stages ...
Cached Medicine News:
... The Eppendorf Mastercycler Family offers fast temperature ... for optimal flexibility. Personal cards enable safe ... reliable transfer of individual protocols between different ... for PCR and come with a two-year ...
96 well thermocycler with unique High Temperature Range (HTR) Peltier technology for fastest available heating and cooling rates up to 4C/sec with High Pressure Lid for automated sealing of PCR plate...
... 40 or 96 temperature cyclers, the gradient block ... range of up to 14 or 22 across ... temperature difference of up to 2C between adjacent ... test up to 12 different annealing temperatures in ...
... performance, high sample throughput instrument at a highly ... Flexible block format, a newly designed flexible heated ... Includes a four year or 80,000 Cycle Warranty! ... connected and run through a PC using Gensoft, ...
Medicine Products: